These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27125973)

  • 1. Evaluation of artemisinins for the treatment of acute myeloid leukemia.
    Drenberg CD; Buaboonnam J; Orwick SJ; Hu S; Li L; Fan Y; Shelat AA; Guy RK; Rubnitz J; Baker SD
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1231-43. PubMed ID: 27125973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
    J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.
    Kumar B; Kalvala A; Chu S; Rosen S; Forman SJ; Marcucci G; Chen CC; Pullarkat V
    Leuk Res; 2017 Aug; 59():124-135. PubMed ID: 28646646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
    Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
    Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs.
    Fox JM; Moynihan JR; Mott BT; Mazzone JR; Anders NM; Brown PA; Rudek MA; Liu JO; Arav-Boger R; Posner GH; Civin CI; Chen X
    Oncotarget; 2016 Feb; 7(6):7268-79. PubMed ID: 26771236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.
    Elmeliegy M; Den Haese J; Talati C; Wetzler M; Jusko WJ
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):325-337. PubMed ID: 32748108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
    Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
    Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
    Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
    Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of Dihydroartemisinin and Arsenic Trioxide on Apoptosis of Acute Myeloid Leukemia Cells].
    Sun WD; Wang X; Wang Y; Tong XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1337-1342. PubMed ID: 36208232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
    Eriksson A; Chantzi E; Fryknäs M; Gullbo J; Nygren P; Gustafsson M; Höglund M; Larsson R
    Leuk Res; 2017 Dec; 63():41-46. PubMed ID: 29100024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
    Tsai HJ; Hsiao HH; Hsu YT; Liu YC; Kao HW; Liu TC; Cho SF; Feng X; Johnston A; Bomalaski JS; Kuo MC; Chen TY
    Cancer Med; 2021 May; 10(9):2946-2955. PubMed ID: 33787078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.
    Drenberg CD; Shelat A; Dang J; Cotton A; Orwick SJ; Li M; Jeon JY; Fu Q; Buelow DR; Pioso M; Hu S; Inaba H; Ribeiro RC; Rubnitz JE; Gruber TA; Guy RK; Baker SD
    Nat Commun; 2019 May; 10(1):2189. PubMed ID: 31097698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification.
    Tian T; Li J; Li Y; Lu YX; Tang YL; Wang H; Zheng F; Shi D; Long Q; Chen M; Garcia-Manero G; Hu Y; Qin L; Deng W
    Theranostics; 2019; 9(13):3768-3779. PubMed ID: 31281512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.
    Kearns P; Zwaan CM; Reinhardt D; Gibson B; Moreno L; Nysom K; Nakahara S; Huang F; Zhou W; Parasrampuria DA; Nemat S
    Br J Haematol; 2019 Aug; 186(3):e7-e11. PubMed ID: 30847896
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin.
    Du J; Wang T; Li Y; Zhou Y; Wang X; Yu X; Ren X; An Y; Wu Y; Sun W; Fan W; Zhu Q; Wang Y; Tong X
    Free Radic Biol Med; 2019 Feb; 131():356-369. PubMed ID: 30557609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.